WGc-0201 injection
WGc-0201/Tislelizumab -HCC
Phase 1 mab active
Quick answer
WGc-0201 injection for Hepatocellular Carcinoma (HCC) is a Phase 1 program (mab) at Xiyuan Hospital of China Academy of Chinese Medical Sciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
- Indication
- Hepatocellular Carcinoma (HCC)
- Phase
- Phase 1
- Modality
- mab
- Status
- active